open access

Vol 47, No 2 (2013)
ARTYKUŁ ORYGINALNY
Submitted: 2012-12-15
Get Citation

Evaluation of efficacy, safety and tolerability of fingolimod in patients with the relapsing form of multiple sclerosis – 12-month observation. A preliminary report

Zdzisław Maciejek, Hanna Wójcik-Drączkowska, Sławomir Wawrzyniak, Anna Niezgodzińska-Maciejek
DOI: 10.5114/ninp.2013.34719
·
Neurol Neurochir Pol 2013;47(2):145-151.

open access

Vol 47, No 2 (2013)
ARTYKUŁ ORYGINALNY
Submitted: 2012-12-15

Abstract

Background and purpose

Oral fingolimod 0.5 mg daily was approved in the European Union in 2011 for the treatment of relapsing multiple sclerosis in the aggressive form and as a second line treatment in patients with high disease activity despite interferon beta therapy. The aim of this study was the evaluation of efficacy, safety and tolerance of fingolimod in patients with relapsing-remitting multiple sclerosis (RRMS) during a 12-month observation period.

Material and methods

The investigated group consisted of 11 patients aged between 23 and 63 years. All patients underwent immunomodulatory treatment (disease modifying drugs – DMD) or immunomodulatory treatment in combination with mitoxantrone (Mx) without a positive effect for 3–5 years. Patients received oral fingolimod 0.5 mg daily during 12 months. Disability was evaluated with Kurtzke Expanded Disability Status Scale (EDSS) scale. Safety and tolerability of fingolimod were evaluated by adverse events monitoring, laboratory tests, and ophthalmological and skin assessment.

Results

Before the initiation of fingolimod treatment all the patients progressed in disability and in MRI changes including five cases with gadolinium-enhancing lesions. During fingolimod treatment there was no new relapse in any patient and no patient stopped the treatment because of any adverse event. During the 12-month treatment, EDSS improvement was observed in seven patients, three patients were stable, and one patient progressed by 0.5 point in the EDSS.

Conclusions

In our study patients fingolimod was effective, safe and well tolerated independently of disease activity and previous treatment.

Abstract

Background and purpose

Oral fingolimod 0.5 mg daily was approved in the European Union in 2011 for the treatment of relapsing multiple sclerosis in the aggressive form and as a second line treatment in patients with high disease activity despite interferon beta therapy. The aim of this study was the evaluation of efficacy, safety and tolerance of fingolimod in patients with relapsing-remitting multiple sclerosis (RRMS) during a 12-month observation period.

Material and methods

The investigated group consisted of 11 patients aged between 23 and 63 years. All patients underwent immunomodulatory treatment (disease modifying drugs – DMD) or immunomodulatory treatment in combination with mitoxantrone (Mx) without a positive effect for 3–5 years. Patients received oral fingolimod 0.5 mg daily during 12 months. Disability was evaluated with Kurtzke Expanded Disability Status Scale (EDSS) scale. Safety and tolerability of fingolimod were evaluated by adverse events monitoring, laboratory tests, and ophthalmological and skin assessment.

Results

Before the initiation of fingolimod treatment all the patients progressed in disability and in MRI changes including five cases with gadolinium-enhancing lesions. During fingolimod treatment there was no new relapse in any patient and no patient stopped the treatment because of any adverse event. During the 12-month treatment, EDSS improvement was observed in seven patients, three patients were stable, and one patient progressed by 0.5 point in the EDSS.

Conclusions

In our study patients fingolimod was effective, safe and well tolerated independently of disease activity and previous treatment.

Get Citation

Keywords

fingolimod, multiple sclerosis – relapsing-remitting form (RRMS)

About this article
Title

Evaluation of efficacy, safety and tolerability of fingolimod in patients with the relapsing form of multiple sclerosis – 12-month observation. A preliminary report

Journal

Neurologia i Neurochirurgia Polska

Issue

Vol 47, No 2 (2013)

Pages

145-151

DOI

10.5114/ninp.2013.34719

Bibliographic record

Neurol Neurochir Pol 2013;47(2):145-151.

Keywords

fingolimod
multiple sclerosis – relapsing-remitting form (RRMS)

Authors

Zdzisław Maciejek
Hanna Wójcik-Drączkowska
Sławomir Wawrzyniak
Anna Niezgodzińska-Maciejek

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl